In:
Cancer Diagnosis & Prognosis, Anticancer Research USA Inc., Vol. 1, No. 5 ( 2021-11-3), p. 379-385
Abstract:
Background/Aim: Diarrhea is among the most common adverse events in early oncology clinical trials, and drug causality may be difficult to determine. Materials and Methods: This is a systematic literature review of placebo arms of randomized cancer trials. Results: Anemia was reported in 95 of 127 placebo monotherapy cohorts. Publications involving healthy volunteers and cancer prevention studies reported lower frequencies than those with cancer patients. The average reported frequency of diarrhea grade 1 or higher among studies in cancer patients was 15%. The maximal reported frequencies for grades 1, 2, 3, 4, 5 were 56, 24, 6, 2, and 0%, respectively. Conclusion: When higher diarrhea frequencies than those are observed in treatment arms of clinical trials, then drug causality is likely.
Type of Medium:
Online Resource
ISSN:
2732-7787
Language:
Unknown
Publisher:
Anticancer Research USA Inc.
Publication Date:
2021
Permalink